CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,100,727 | -15.4% | 68,313 | +4.7% | 0.06% | -11.9% |
| Q2 2023 | $3,663,135 | +32.6% | 65,250 | +6.9% | 0.07% | +21.8% |
| Q1 2023 | $2,761,518 | +37.9% | 61,055 | +24.0% | 0.06% | +27.9% |
| Q4 2022 | $2,002,013 | -42.4% | 49,250 | -7.4% | 0.04% | -44.9% |
| Q3 2022 | $3,476,000 | +31.1% | 53,189 | +21.9% | 0.08% | +110.8% |
| Q2 2022 | $2,651,000 | +16.7% | 43,625 | +20.6% | 0.04% | +48.0% |
| Q1 2022 | $2,271,000 | -41.8% | 36,181 | -29.7% | 0.02% | -30.6% |
| Q4 2021 | $3,899,000 | -29.1% | 51,445 | +4.7% | 0.04% | -32.1% |
| Q3 2021 | $5,502,000 | -36.2% | 49,158 | -7.7% | 0.05% | -31.2% |
| Q2 2021 | $8,624,000 | +0.1% | 53,272 | -24.7% | 0.08% | -3.8% |
| Q1 2021 | $8,619,000 | -52.6% | 70,735 | -40.4% | 0.08% | -52.4% |
| Q4 2020 | $18,166,000 | +94.3% | 118,647 | +6.1% | 0.17% | +63.1% |
| Q3 2020 | $9,349,000 | – | 111,780 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |